Bluejay Diagnostics, Inc. (NASDAQ: BJDX) saw a significant pre-market rally on Tuesday, July 7, 2026, with shares quoted at $1.47 as of 9:00 a.m. ET. This represented a 26.7% increase from the prior close of $1.16. However, the stock still traded below key financing thresholds, including the $2.075 exercise price on Series G and Series H warrants and the $2.325 private-placement price from June.
Pre-Market Activity
Pre-market volume reached 35.93 million shares, approximately 3.2 times the 11.22 million shares covered by Bluejay's June 26 resale prospectus. The stock's pre-market range was $1.43 to $1.48, according to Public.com. Earlier, Benzinga had listed Bluejay among Tuesday's pre-market gainers, with the stock up as much as 35.3% to $1.57 at one point.
Market Data Snapshot
- Pre-market quote: $1.47 at 9:00 a.m. ET (up 26.7% from $1.16 close)
- Pre-market volume: 35.93 million shares (3.2x the resale share pool)
- Prior close: $1.16 (up 1.75% on Monday)
- Market cap: Approximately $1.20 million
- Shares outstanding: 1.03 million
- 52-week range: $1.03 to $16.68
June Financing Context
The June 26 prospectus covers resale by selling stockholders of up to 11,223,665 common shares, primarily tied to pre-funded warrants, Series G warrants, and Series H warrants issued in the June financing. Bluejay is not selling shares under that prospectus and will not receive proceeds from selling-stockholder sales, though it would receive cash if warrants are exercised for cash.
Key Financing Terms
- Private-placement price: $2.325 per share or pre-funded warrant plus warrants (stock was 36.8% below)
- Series G/H warrant exercise price: $2.075 per share (stock was 29.2% below)
- Upfront gross proceeds: $8.5 million (about 7.1x the screen market cap)
- Potential warrant proceeds: About $15.2 million (not assured)
Warrant Exercise Uncertainty
Bluejay stated that the Series G and short-term Series H warrants are immediately exercisable at $2.075 per share, but no assurance can be given that any series warrants will be exercised. The company reported gross proceeds of $8.5 million before expenses, with potential additional gross proceeds of about $15.2 million if those warrants are exercised in full for cash.
Use of Proceeds and Operational Update
Bluejay plans to use net proceeds to fund matters tied to FDA approval, including clinical studies, as well as other research and development and working-capital needs. The June 5 release indicated that proceeds were expected to extend the cash runway into the first quarter of 2027, beyond its expected FDA submission. As of March 31, cash and equivalents stood at approximately $3.7 million, with a first-quarter net loss of about $1.9 million. CEO Neil Dey noted 'strong enrollment momentum' in the SYMON-II study, with about 680 patients enrolled against a 750-patient target.
Regulatory and Manufacturing Developments
In its June prospectus, Bluejay noted that Symphony does not yet have FDA clearance and requires FDA authorization before marketing in the United States. The company expects SYMON-II enrollment to finish in summer 2026 and aims to submit a 510(k) application to the FDA in the first half of 2027, subject to funding, manufacturing, and validation work. On June 2, Bluejay announced a partnership with Argonaut Manufacturing Services to move part of its manufacturing base closer to the U.S. market, aiming for a 'scalable and quality-focused operational foundation.'
Capital Structure Challenges
Bluejay has carried out four reverse stock splits since July 2023, equal to a 1-for-32,000 aggregate split, after its share price fell below Nasdaq's $1 minimum bid rule. The company listed six full-time employees as of June 17. The capital structure remains a key challenge as the stock trades well below the warrant exercise prices, creating uncertainty around potential warrant proceeds.
